Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer
BASEL, Switzerland – 3rd December 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, announces the appointment of Eckhard Niemeier as its Chief Business Officer (CBO). With over 20 years of experience in life sciences corporate development and strategy, Eckhard will work closely with the leadership team and play a key role in shaping Nouscom’s growth.
Dr. Marina Udier, CEO of Nouscom, commented on the appointment: “We are delighted to welcome Eckhard to Nouscom. His proven track record in forging collaborations with leading pharmaceutical and biotech companies aligns perfectly with our vision for growth and innovation. The next 12 months will be an exciting time for Nouscom as we anticipate key data readouts from clinical trials with our lead asset, NOUS-209, in dMMR/MSI metastatic CRC and in Lynch Syndrome carriers. I look forward to working with Eckhard and the leadership team to shape the next phase of growth for the company, leveraging both our pipeline opportunities, such as NOUS-PEV, and the broad potential of our innovative platform.”
Eckhard joins Nouscom from UNION Therapeutics A/S, where he served as CBO and was responsible for all business and corporate development activities, including in- and out-licensing, M&A, and alliance management. His leadership was instrumental in advancing UNION’s portfolio and corporate strategy. Previously, he held senior roles at Pieris Pharmaceuticals, where he established strategic deals with major companies including AstraZeneca, Roche/Genentech, Seagen and Servier. Before Pieris, Eckhard worked at Gruenenthal Pharma and MorphoSys, managing licensing and partnerships across all drug development stages. He began his career at McKinsey & Company focusing on healthcare and life sciences. Eckhard holds a master’s degree in biotechnology and completed his thesis at Human Genome Sciences.
Mr. Eckhard Niemeier, CBO, added: “I am excited to join Nouscom at such a key moment. The company’s strong pipeline of off-the-shelf and personalized neoantigen cancer immunotherapies, along with its innovative platform, present great opportunities for external partnerships. I look forward to working with the team to unlock value and deliver potentially meaningful cancer treatments to patients.”
